Core Insights - Royalty Pharma and Ascendis Pharma have entered into a $150 million capped synthetic royalty funding agreement based on U.S. net sales of Yorvipath, the first FDA-approved treatment for hypoparathyroidism in adults [1][2] Group 1: Agreement Details - Ascendis Pharma will receive an upfront payment of $150 million in exchange for a 3% royalty on U.S. net sales of Yorvipath [2] - Royalty payments to Royalty Pharma will cease upon reaching a multiple of 2.0x, or 1.65x if royalties are received by December 31, 2029 [2] Group 2: Company Profiles - Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation in the biopharmaceutical industry, with a portfolio that includes royalties on over 35 commercial products [4] - Ascendis Pharma focuses on developing new therapies using its innovative TransCon technology platform, aiming to make a meaningful difference in patients' lives [5]

Core Viewpoint - Royalty Pharma reported quarterly earnings of $0.96 per share, exceeding the Zacks Consensus Estimate of $0.95 per share, and showing an increase from $0.85 per share a year ago, indicating a positive earnings surprise of 1.05% [1] Financial Performance - The company achieved revenues of $608 million for the quarter ended June 2024, surpassing the Zacks Consensus Estimate by 1.19% and up from $545 million in the same quarter last year [2] - Over the last four quarters, Royalty Pharma has exceeded consensus EPS estimates three times and has also topped consensus revenue estimates three times [2] Stock Performance and Outlook - Royalty Pharma shares have declined approximately 3% since the beginning of the year, contrasting with the S&P 500's gain of 9% [3] - The company's future stock performance will largely depend on management's commentary during the earnings call and the revisions of earnings estimates [3][4] Earnings Estimates - The current consensus EPS estimate for the upcoming quarter is $0.91, with expected revenues of $670.03 million, and for the current fiscal year, the consensus EPS estimate is $3.96 on revenues of $2.68 billion [7] Industry Context - The Financial - Miscellaneous Services industry, to which Royalty Pharma belongs, is currently ranked in the top 37% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]

Company Overview - Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation in the biopharmaceutical industry, founded in 1996 [2] - The company collaborates with innovators from academic institutions, research hospitals, non-profits, and biopharmaceutical companies, funding innovation directly and indirectly [2] - Royalty Pharma's portfolio includes royalties on over 35 commercial products and 17 development-stage product candidates, such as Vertex's Trikafta, GSK's Trelegy, Roche's Evrysdi, and others [2] Leadership Appointment - Molly Sawaya has been appointed as Executive Vice President, Head of Human Capital at Royalty Pharma [4] - Molly brings nearly 15 years of HR experience from large global organizations, including Hudson Bay Capital, QBE Insurance Group, Perpetual Limited, and National Australia Bank [1][8] - Her role will focus on fostering a culture of growth and supporting the scaling of the business [8] Business Model - Royalty Pharma funds innovation directly by partnering with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties [2] - Indirectly, the company acquires existing royalties from original innovators, building a portfolio tied to the top-line sales of leading therapies [2]

Core Insights - Royalty Pharma plc has appointed Molly Sawaya as Executive Vice President, Head of Human Capital, effective July 24, 2024 [1][4] Company Overview - Royalty Pharma, founded in 1996, is the largest buyer of biopharmaceutical royalties and a leading funder of innovation in the biopharmaceutical industry [8] - The company collaborates with various entities, including academic institutions, research hospitals, non-profits, and biotechnology companies, to fund innovation [8] - Royalty Pharma's portfolio includes royalties on over 35 commercial products, such as Vertex's Trikafta and GSK's Trelegy, as well as 17 development-stage product candidates [8] Leadership Appointment - Molly Sawaya brings nearly 15 years of HR experience from large global organizations, focusing on creating environments for employee growth and engagement [4][7] - Prior to joining Royalty Pharma, Sawaya was a Managing Director at Hudson Bay Capital, where she led the HR agenda [7] - The CEO of Royalty Pharma, Pablo Legorreta, expressed confidence in Sawaya's ability to enhance the company's culture and support its growth [4]

NEW YORK, July 19, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its second quarter 2024 financial results on Thursday, August 8, 2024 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day. Please visit the "Investors" page of the company's website at https://www.royaltypharma.com/investors/events/ to obtain conference call information and to view the live webcast. A replay ...

Group 1 - Royalty Pharma, founded in 1996, is the largest buyer of biopharmaceutical royalties and a key funder of innovation in the biopharmaceutical industry [1] - The company collaborates with various entities, including academic institutions, research hospitals, non-profits, small and mid-cap biotechnology companies, and leading global pharmaceutical companies [1] - Royalty Pharma's portfolio includes royalties on over 35 commercial products and 17 development-stage product candidates, featuring notable therapies such as Vertex's Trikafta and GSK's Trelegy [1] Group 2 - The board of directors of Royalty Pharma has approved a dividend of $0.21 per Class A ordinary share for the third quarter of 2024 [2] - The dividend payment is scheduled for September 13, 2024, to shareholders of record as of August 16, 2024 [4]

The bullish case only gets stronger once investors take into account RPRX's positive earnings estimate revisions. There have been 1 higher compared to none lower for the current fiscal year, and the consensus estimate has moved up as well. From a technical perspective, Royalty Pharma (RPRX) is looking like an interesting pick, as it just reached a key level of support. RPRX recently overtook the 50-day moving average, and this suggests a short-term bullish trend. The 50-day simple moving average is a widely ...

Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Royalty Pharma (RPRX) , which belongs to the Zacks Financial - Miscellaneous Services industry, could be a great candidate to consider. For the most recent quarter, Royalty Pharma was expected to post earnings of $0.96 per share, but it reported $0.98 per share instead, representing a surprise of 2.08%. For the previous quarter, the consensus estimate ...

Company Overview - Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation in the biopharmaceutical industry, collaborating with various entities from academic institutions to global pharmaceutical companies [2] - The company has a portfolio that includes royalties on more than 35 commercial products, such as Vertex's Trikafta, GSK's Trelegy, and Roche's Evrysdi, as well as 17 development-stage product candidates [2] Upcoming Events - Royalty Pharma is scheduled to participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference on June 11, 2024, at 2:00 p.m. ET, with the webcast accessible on their "Events" page [1]

NEW YORK, June 03, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today that it has priced an offering of $1.5 billion of senior unsecured notes, comprised of the following (collectively, the "Notes"): $500 million of 5.150% Notes due 2029 (the "2029 Notes"); $500 million of 5.400% Notes due 2034 (the "2034 Notes"); and $500 million of 5.900% Notes due 2054 (the "2054 Notes"). The Notes will be guaranteed on a senior unsecured basis by Royalty Pharma Holdings Ltd. The offering is expec ...